Mortality associated with resistant cytomegalovirus among patients with cytomegalovirus retinitis and AIDS

Ophthalmology. 2010 Jan;117(1):128-132.e2. doi: 10.1016/j.ophtha.2009.06.016. Epub 2009 Oct 8.

Abstract

Objective: To evaluate the effect of drug-resistant cytomegalovirus (CMV) on survival among patients with CMV retinitis.

Design: Prospective cohort study during 1993 to 2003.

Participants: We included 266 patients with AIDS and newly diagnosed CMV retinitis treated with either ganciclovir or foscarnet.

Methods: Data on ganciclovir and foscarnet resistance were obtained from blood and urine specimens collected at regular, predetermined intervals. The effect of resistant CMV on mortality was evaluated with a time-dependent Cox proportional hazard model.

Main outcome measures: Mortality.

Results: The median survival of the entire cohort was 12.6 months. Analysis of risk factors for mortality demonstrated that resistant CMV was associated with an increased mortality (hazard ratio, 1.65; 95% confidence interval, 1.05-2.56; P = 0.032). Among the other parameters tested, only time since AIDS diagnosis was associated significantly with mortality, with a hazard ratio of 1.10 per year since AIDS diagnosis (P = 0.001).

Conclusions: Resistant CMV is associated with increased mortality among patients with AIDS being treated for CMV retinitis.

Financial disclosure(s): Proprietary or commercial disclosure may be found after the references.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy
  • AIDS-Related Opportunistic Infections / mortality*
  • AIDS-Related Opportunistic Infections / virology
  • Adult
  • Antiretroviral Therapy, Highly Active
  • Antiviral Agents / therapeutic use*
  • Cytomegalovirus / isolation & purification
  • Cytomegalovirus / physiology*
  • Cytomegalovirus Retinitis / drug therapy
  • Cytomegalovirus Retinitis / mortality*
  • Cytomegalovirus Retinitis / virology
  • Drug Resistance, Viral*
  • Female
  • Foscarnet / therapeutic use
  • Ganciclovir / therapeutic use
  • Humans
  • Male
  • Proportional Hazards Models
  • Prospective Studies
  • Survival Rate
  • Time Factors
  • Viral Load

Substances

  • Antiviral Agents
  • Foscarnet
  • Ganciclovir